Inozyme Pharma (INZY)
(Delayed Data from NSDQ)
$5.18 USD
+0.25 (5.07%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $5.17 -0.01 (-0.19%) 7:12 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Inozyme Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 76 | 69 | 57 | 57 | 21 |
Income After Depreciation & Amortization | -76 | -69 | -57 | -57 | -21 |
Non-Operating Income | 8 | 2 | 0 | 1 | 1 |
Interest Expense | 3 | 0 | 0 | 0 | 0 |
Pretax Income | -71 | -67 | -57 | -56 | -20 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -71 | -67 | -57 | -56 | -20 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -71 | -67 | -57 | -56 | -20 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -80 | -70 | -56 | -57 | -21 |
Depreciation & Amortization (Cash Flow) | -5 | -1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -76 | -69 | -57 | -57 | -21 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 51.84 | 37.76 | 23.56 | 11.04 | NA |
Diluted EPS Before Non-Recurring Items | -1.37 | -1.78 | -2.40 | -5.11 | NA |
Diluted Net EPS (GAAP) | -1.37 | -1.78 | -2.40 | -5.11 | NA |
Fiscal Year end for Inozyme Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 27.67 | 24.34 | 22.81 | 18.07 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -27.67 | -24.34 | -22.81 | -18.07 |
Non-Operating Income | NA | 2.03 | 2.32 | 4.60 | 1.44 |
Interest Expense | NA | 1.40 | 1.33 | 3.33 | 0.00 |
Pretax Income | NA | -27.03 | -23.35 | -21.54 | -16.64 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -27.03 | -23.35 | -21.54 | -16.64 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -27.03 | -23.35 | -21.54 | -16.64 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 61.94 | 61.77 | 51.84 | 56.76 |
Diluted EPS Before Non-Recurring Items | NA | -0.44 | -0.38 | -0.35 | -0.29 |
Diluted Net EPS (GAAP) | NA | -0.44 | -0.38 | -0.33 | -0.29 |